Jim Delshad
CIK: 0001605790
Jim Delshad's purchase track record
How the stock did after each of Jim Delshad's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
Purchases measured
3
of 3 since March 26, 2025
Stock higher 6 months later
67%
3 months: 0%
Median 6-month return
+50.8%
3 months: -36.5%
Beat the S&P 500
67%
median +25.3% vs. index
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 5/12/2025 | NTHI | $36K | -16.5% | +65.7% | +16.9% |
| 4/17/2025 | NTHI | $346 | -36.5% | +50.8% | +25.5% |
| 3/26/2025 | NTHI | $802 | -69.3% | -0.9% | +16.2% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| NTHI | ▲ Buy | Open Market | 5,000 | $36K | 5/12/2025 | View on chart |
| NTHI | ▲ Buy | Open Market | 50 | $346 | 4/17/2025 | View on chart |
| NTHI | ▲ Buy | Open Market | 50 | $802 | 3/26/2025 | View on chart |
| NTHI | ▲ Buy | Grant | 50,000 | $0 | 3/26/2025 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 28, 2026
NeOnc Sets FDA Meeting for NEO212; Roth Starts Coverage
NeOnc Technologies has scheduled an in-person FDA End-of-Phase 1 meeting for November 17 regarding its NEO212 candidate. This regulatory milestone provides a clear next step for the company's development timeline. Additionally, Roth Capital initiated coverage with a price target of $20, which is at the top of the current analyst range.
NeOnc Sets FDA Meeting for NEO212; Roth Starts Coverage. NeOnc Technologies has scheduled an in-person FDA End-of-Phase 1 meeting for November 17 regarding its NEO212 candidate. This regulatory milestone provides a clear next step for the company's development timeline. Additionally, Roth Capital initiated coverage with a price target of $20, which is at the top of the current analyst range.